Anti-Neoplastic Agents Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The antiparasitic drugs market size has grown strongly in recent years. It will grow from $24.06 billion in 2024 to $25.75 billion in 2025 at a compound annual growth rate (CAGR) of 7%. The growth in the historic period can be attributed to prevalence of parasitic infections, resistance to existing treatments, global health initiatives,.

The antiparasitic drugs market size is expected to see strong growth in the next few years. It will grow to $33.64 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to emerging parasitic threats, climate change and vector-borne diseases, increased emphasis on global health security, access to healthcare. Major trends in the forecast period include advances in drug development, targeted therapies, combination therapies, public-private partnerships, telemedicine and remote diagnosis.

The increasing incidence of vector-borne diseases is expected to significantly drive the growth of the antiparasitic drugs market. Vector-borne diseases, which are transmitted to humans through the bites of insects such as mosquitoes, ticks, and flies, include conditions like malaria, dengue, and yellow fever. Antiparasitic drugs play a vital role in controlling and eliminating the parasites responsible for these diseases, helping to reduce their spread and impact on public health. For example, drugs like chloroquine, doxycycline, and atovaquone-proguanil are commonly used to treat malaria. According to the Centers for Disease Control and Prevention (CDC), in June 2024, over 9.7 million dengue cases were reported across the Americas, more than double the 4.6 million cases in 2023. In the U.S., Puerto Rico alone reported 1,498 dengue cases, with 745 cases among travelers returning from affected areas. This rise in vector-borne diseases underlines the critical need for effective antiparasitic treatments, further driving the growth of the antiparasitic drugs market.

The high prevalence of parasitic infections is expected to significantly drive the growth of the antiparasitic drug market. Parasitic infections, caused by organisms such as protozoa, worms, and rickettsia, pose a serious health threat and can lead to conditions ranging from mild illness to severe, life-threatening diseases. Antiparasitic drugs are crucial for treating these infections, helping to alleviate symptoms, prevent complications, and improve overall health outcomes. According to a May 2024 report by Gov. UK, in 2022, 31 rickettsial infection cases were reported in England and Wales, highlighting the persistence of parasitic infections. With ongoing challenges in managing parasitic diseases globally, the demand for effective antiparasitic treatments is expected to continue growing, further propelling the market.

Major companies operating in the antiparasitic drugs market are increasingly focusing on the development of innovative products, such as chewable veterinary medications, to improve ease of administration and enhance pet compliance. These chewable products are typically flavored, making them more appealing to pets and reducing the stress often associated with administering medications. For example, in April 2024, C.H. Boehringer Sohn AG & Co. KG, a Germany-based pharmaceutical company, launched NexGard Spectra. This soft, flavorful chew provides comprehensive parasite control for dogs, targeting fleas, ticks, heartworms, and various intestinal worms. NexGard Spectra is a highly effective treatment, killing fleas within four hours of administration and offering over 99% effectiveness against multiple parasites with a single monthly dose, further enhancing convenience and compliance for pet owners.

In June 2022, Orion Corporation, a pharmaceutical company headquartered in Finland, completed the acquisition of Inovet BV's animal health division for $141 million (€130 million). This strategic acquisition is anticipated to bolster Orion Corporation's presence in Western Europe and export markets, and it will also grant them access to a dedicated production facility specializing in the manufacturing of veterinary medicines. Inovet BV, based in Belgium, is a renowned veterinary pharmaceutical company known for its wide range of products, including antiparasitic treatments, antibiotics, and vaccines.

Major companies operating in the antiparasitic drugs market are Pfizer Inc., Johnson & Johnson, Cadila Pharmaceuticals, Merck & Co.Inc., Bayer AG, Novartis AG, Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim group, Zoetis Inc., Eisai Co. Ltd., Covetrus Inc., IDEXX Laboratories Inc., Dr. Reddy's Laboratories, Intas Pharmaceuticals Ltd., Alkem Laboratories Ltd., Ceva Sante Animale S.A., Elanco Animal Health Incorporated, Phibro Animal Health Corporation, Norbrook Laboratories Ltd., Mankind Pharma, Neogen Corporation, Bimeda Inc., Indoco Remedies Ltd., ECO Animal Health, Lincoln Pharmaceuticals Ltd., Laboratorios Calier.

North America was the largest region in the antiparasitic drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in antiparasitic drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the antiparasitic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The antiparasitic drugs market consists of sales of antimalarial drugs, antiamoebic drugs, anti-trematode drugs and veterinary products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Antiparasitic drugs encompass a category of medications designed to combat infections triggered by a variety of parasites that have the potential to infest humans, animals, or plants. Parasites are living organisms that either reside on or within a host organism, drawing sustenance from it and often causing harm in the process. Antiparasitic drugs are formulated to specifically target these parasites, either by exterminating them or inhibiting their growth.

The primary product categories within antiparasitic drugs include anthelmintics, antiprotozoals, ectoparasiticides, and other related treatments. Anthelmintics, for instance, are a class of drugs tailored to address infections caused by parasitic worms. They operate by either eradicating the parasites or stunting their growth and reproductive capabilities. A diverse range of treatments falls under this category, including avermectins, benzimidazoles, pyrimidines, organophosphates, and imidazole thiazoles. These treatments can be administered through various means, such as orally, through injections, or topically, and are employed across a spectrum of end-users, including hospitals, homecare settings, specialty clinics, and others.

The antiparasitic drugs market research report is one of a series of new reports that provides antiparasitic drugs market statistics, including antiparasitic drugs industry global market size, regional shares, competitors with an antiparasitic drugs market share, detailed antiparasitic drugs market segments, market trends and opportunities and any further data you may need to thrive in the antiparasitic drugs industry. This antiparasitic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.